IE 11 is a very old Browser and it`s not supported on this site
bbbiotech.ch
Contact
de
en
it
Annual Report 2022
Annual Report 2022
Business report
Shareholder letter
Performance/Multi-year comparison
Video Update Dr. Daniel Koller
Portfolio Update Q4 2022
Outlook
Portfolio at a glance
Portfolio interactive
Financial report
Consolidated financial statements
Consolidated balance sheet as at December 31
Consolidated statement of comprehensive income for the year ended December 31
Consolidated statement of changes in equity for the year ended December 31
Consolidated statement of cash flow for the year ended December 31
Notes to the consolidated financial statements
Report on the audit of the consolidated financial statements
Financial statements BB Biotech AG
Balance sheet as at December 31
Statement of income for the year ended December 31
Notes to the financial statements BB Biotech AG
Report on the audit of the financial statements
Corporate Governance
Corporate Governance
1. Introductory remarks with respect to the specific structure of BB Biotech AG as an investment company
2. Group structure and shareholders
3. Capital structure
4. Limitations on transferability
5. Board of Directors
6. Investment management
7. Remuneration
8. Shareholders’ participation rights
9. Change-of-control and defensive measures
10. Audits
11. Trading in own securities
12. Information policy
13. Trading blackout periods
Remuneration Report
Remuneration Report
1. Responsibilities and authorities with respect to remuneration
2. Remuneration of the members of the Board of Directors
3. Remuneration of related parties at non-market conditions
4. Remuneration of former members of the corporate bodies
5. Loans and credits to the members of the Board of Directors
6. Contractual terms at retirement from BB Biotech AG
7. Management contracts
ESG
Foreword
Sustainability achievements
Sustainability Strategy
Sustainable Development Goals (SDGs)
Sustainability at Board of Directors level
Sustainability at Investment Manager level
Sustainability at BB Biotech AG’s portfolio level
Annex
About us
Company Profile
Shareholder information
Corporate calendar
Facts & figures
Investment strategy
Investment process
Board of Directors
Investment Manager
Contact
Contact
de
en
it
Kennzahlenvergleich EN
Company selection
Ionis Pharmaceuticals
Moderna
Neurocrine Biosciences
Argenx SE
Incyte
Agios Pharmaceuticals
Vertex Pharmaceuticals
Fate Therapeutics
Macrogenics
Alnylam Pharmaceuticals
Rivus Pharmaceuticals
Arvinas
Sage Therapeutics
Intra-Cellular Therapies
Crispr Therapeutics
Esperion Therapeutics
Scholar Rock Holding
Myovant Sciences
Molecular Templates
Generation Bio Co.
Relay Therapeutics
Exelixis
Black Diamond Therapeutics
Essa Pharma
Celldex Therapeutics
Revolution Medicines
Beam Therapeutics
Mersana Therapeutics
Kezar Life Sciences
Homology Medicines
Wave Life Sciences
Figures
Bar Chart View
Line Chart View
Table View
XLS
PNG
Print
Return to the portfolio
BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.
Use of cookies & disclaimer
Accept cookies